- “Glimepiride Tablets” already exists in your wishlist
In Stock
Osimertinib Tablets
Osimertinib Tablets 40mg | Anti-Cancer
- Product Form: Raw Powder / API
- Not for direct consumer use
- For qualified buyers, formulation, compounding, R&D, and regulated business use only
- COA/MSDS available upon request
- Final sale depends on buyer country import regulations
Disclaimer: Products listed on this website are intended for qualified business buyers, research, formulation, compounding, or regulated pharmaceutical use only. Products are not intended for direct consumer use. Import permission, registration, customs clearance, and local regulatory compliance are the responsibility of the buyer in their respective country.
Description
Generic medicine information • For patient education
Product Introduction
Osimertinib 40 mg is a prescription anti-cancer medicine from the tyrosine kinase inhibitor (TKI) class. It is used for selected adults with non-small cell lung cancer (NSCLC) whose tumour has specific EGFR (epidermal growth factor receptor) mutations. Testing of the tumour is generally needed to confirm whether this treatment is appropriate.
Treatment must be supervised by an oncology specialist. The 40 mg strength does not mean that every patient should take 40 mg; use only the dose and schedule prescribed for you.
1. Uses
Used for certain types of non-small cell lung cancer in adults with specific EGFR mutations, according to the approved indication and treatment plan chosen by the oncologist.
Whether it is appropriate depends on tumour test results, cancer stage, prior treatment, and the current prescribing information.
2. Benefits
Targets abnormal EGFR signalling involved in the growth of some cancer cells.
In eligible patients, it may shrink tumours or slow cancer progression. Results vary between individuals, and it is not a guaranteed cure.
3. Side Effects
Common or reported effects include diarrhoea, rash, dry skin, mouth inflammation (stomatitis), fatigue, reduced appetite, nail changes, muscle/joint/bone pain, anaemia, and low white blood cell or platelet counts.
Serious risks can include inflammation of the lungs (interstitial lung disease/pneumonitis), heart muscle problems, QT prolongation or abnormal heart rhythm, severe skin reactions, and rare severe bone-marrow problems.
Seek urgent medical advice for new or worsening shortness of breath, cough or fever; chest pain, fainting, or a fast/irregular heartbeat; severe or blistering skin rash; unusual bleeding or bruising; or severe/persistent diarrhoea or dehydration.
4. Safety Advice
Pregnancy: may harm an unborn baby. Tell your oncology team if pregnant, planning pregnancy, or if pregnancy is possible. Follow their advice on effective contraception during treatment and for the recommended period after the last dose.
Breastfeeding: do not breastfeed during treatment and for the period advised by your specialist after the last dose.
Heart and lung monitoring: attend scheduled checks. Tell your clinician about heart rhythm problems, heart failure, lung disease, or previous serious treatment reactions.
Kidney or liver disease: inform your clinician, particularly if you have severe kidney or liver problems.
Alcohol: ask your oncology team whether alcohol is appropriate during treatment.
Driving: do not drive or operate machinery if dizzy, sleepy, visually impaired, or otherwise unwell.
Storage: store below 30°C, in the original packaging and out of reach of children, unless the package leaflet says otherwise.
5. How It Works
Osimertinib blocks abnormal EGFR tyrosine kinase signalling in cancer cells with susceptible EGFR mutations. This can interrupt signals that help those cells grow and divide.
6. How to Use
Take exactly as prescribed by your oncologist. The dose and duration depend on your diagnosis, treatment plan, side effects, and clinical response.
It may be taken with or without food. Try to take it at the same time each day.
Swallow the tablet whole with water. Do not chew, crush, or split it unless your oncology team gives specific instructions.
If you miss a dose, follow the package leaflet or contact your oncology team. Do not take an extra dose to make up for a missed dose.
If you vomit after taking a dose, do not take an additional dose unless your oncology team instructs you to.
Do not stop treatment or change the dose without speaking to your oncologist.
7. Quick Tips
Keep a current list of prescription medicines, over-the-counter medicines, vitamins, and herbal supplements and share it with your oncology team.
Check with your doctor or pharmacist before starting any new medicine or supplement. Avoid St John’s wort unless specifically approved by your clinician.
Follow your care team's advice about grapefruit and grapefruit juice; the 1mg product page advises avoiding them.
Drink fluids if diarrhoea occurs. Contact your care team if it is severe, persistent, bloody, or associated with dehydration.
Protect your skin from excessive sun exposure and report severe rash or skin peeling.
Attend recommended blood tests and heart/lung assessments.
8. Drug Interactions
Osimertinib can interact with medicines that affect drug-metabolising enzymes and with medicines that prolong the QT interval or affect heart rhythm.
Some antifungals and heart-rhythm medicines may be important interaction risks. Do not start or stop medicines such as fluconazole, selected anti-seizure medicines, rifampicin, St John’s wort, or heart-rhythm medicines without professional review.
This is not a complete interaction list. Give your oncologist and pharmacist a complete list of all medicines and supplements so they can check the exact combination.
Medical Disclaimer
This document is for general patient education only and is not a substitute for advice from a qualified doctor, oncology specialist, or pharmacist. Osimertinib is a potent prescription anti-cancer medicine and must be used only under specialist supervision. The correct indication, dose, monitoring, precautions, and management of side effects depend on the individual patient and current approved product information. In an emergency, seek urgent medical care.
| Product Name | Osimertinib Tablets |
| Category | All Medicines, Anti Cancer |
| Form | Raw Powder |
| Grade | As per available specification |
| Documents | COA, MSDS, Invoice, Packing List |
| Packing | As per order quantity |
| MOQ | On request |
| Shipment | Air cargo / courier / buyer-approved route |
| Use | B2B, formulation, compounding, research & qualified buyer supply |
| Disclaimer | Subject to buyer country regulations |
Additional information
| Strength | 40mg |
|---|
Customer Reviews
Only logged in customers who have purchased this product may leave a review.
